Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Did you miss out on key UPSC current affairs tidbits? Here's a quick checklist of must-know facts — learn about new ASEAN ...

PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

In line with the observance of Newborn Screening (NBS) Month this October and Newborn Screening Awareness Week in its first week, medical experts have reiterated the importance of this simple yet life ...

Dr. MacKenzie and her team at UCSF are using hematopoietic stem cells (HSCs) to treat babies in the womb who have alpha thalassemia major, a blood disorder that is almost always fatal. Current… ...

Alpha thalassemia is one of the most common hemoglobinopathies worldwide, caused by mutations in the HBA1 and HBA2 genes. Patients with the severe disease form are at high risk of fetal demise without ...